# Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

> **NCT03768505** · PHASE2 · TERMINATED · sponsor: **MEI Pharma, Inc.** · enrollment: 169 (actual)

## Conditions studied

- Follicular Lymphoma (FL)
- Non Hodgkin Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Zandelisib (ME-401)

## Key facts

- **NCT ID:** NCT03768505
- **Lead sponsor:** MEI Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-25
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-03-24
- **Target enrollment:** 169 (ACTUAL)
- **Why stopped:** discontinuation of zandelisib program
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768505, "Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03768505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*